
Claims

1. A compound of formula (I)




(I)

wherein

A^1 is selected from the group consisting of CH and N;

A^2 is selected from the group consisting of CR^{19} and N, provided that A^1 and A^2 are not N simultaneously;



is aryl or heteroaryl, wherein said aryl and said heteroaryl are optionally substituted by 1 to 3 substituents independently selected from the group consisting of ~~lower~~ C_{1-7} alkyl, ~~lower~~ C_{1-7} alkoxy, ~~lower~~ C_{1-7} hydroxyalkyl, ~~lower~~ C_{1-7} haloalkyl, ~~lower~~ C_{1-7} -alkoxy- C_{1-7} ~~lower~~-alkyl, ~~lower~~ C_{1-7} alkyl-C(O)-, -C(O)-N(R^8)$_2$, -N(R^8)-C(O)-~~lower~~ C_{1-7} alkyl, cyano, halogen, R^9 and amino, and wherein said ~~lower~~ C_{1-7} alkyl is optionally substituted by oxo, -C(O)OH, ~~lower~~ C_{1-7} alkoxy-C(O)- or R^7, and wherein said ~~lower~~ C_{1-7} alkoxy is optionally substituted by hydroxyl, C_{1-7} ~~lower~~ alkoxy or -C(O)-N(R^8)$_2$, and wherein said amino is optionally substituted by 1 or 2 substituents independently selected from the group consisting of ~~lower~~ C_{1-7} alkyl, ~~lower~~ C_{1-7} hydroxyalkyl, ~~lower~~ C_{1-7} -alkoxy- ~~lower~~ C_{1-7} -alkyl and ~~lower~~ C_{1-7} alkyl-C(O)-;

R^1 is ~~lower~~ C_{1-7} alkyl, ~~lower~~ C_{1-7} alkoxy, ~~lower~~ C_{1-7} hydroxyalkyl, ~~lower~~ C_{1-7} haloalkyl, ~~lower~~ C_{1-7} -alkoxy- ~~lower~~ C_{1-7} -alkyl, ~~lower~~ C_{1-7} alkyl-C(O)-, -O-~~lower~~ C_{1-7} haloalkyl, cyano, halogen, R^7 or amino, wherein said ~~lower~~ C_{1-7} alkyl is optionally substituted by R^7, and wherein said amino is optionally

substituted by 1 or 2 substituents independently selected from the group consisting of ~~lower~~ C_{1-7} alkyl and ~~lower~~ C_{1-7}-alkoxy-~~lower~~ C_{1-7}-alkyl;

R^2 and R^3 are independently hydrogen or ~~lower~~ C_{1-7} alkyl;

R^4 is aryl or heteroaryl, wherein said aryl and said heteroaryl are optionally substituted by 1 to 3 substituents independently selected from the group consisting of hydroxyl, halogen, ~~lower~~ C_{1-7} alkyl, ~~lower~~ C_{1-7} alkoxy, ~~lower~~ C_{1-7} hydroxyalkyl, ~~lower~~ C_{1-7} haloalkyl, ~~lower~~ C_{1-7}-alkoxy-~~lower~~ C_{1-7}-alkyl, ~~lower~~ C_{1-7} alkyl-C(O)-, cyano and amino, and wherein said amino is optionally substituted by 1 or 2 substituents independently selected from the group consisting of ~~lower~~ C_{1-7} alkyl and ~~lower~~ C_{1-7}-alkoxy-~~lower~~ C_{1-7}-alkyl;

R^5 and R^6 are independently hydrogen, ~~lower~~ C_{1-7} alkyl, ~~lower~~ C_{1-7} alkoxy, ~~lower~~ C_{1-7} haloalkyl, ~~lower~~ C_{1-7} cyanoalkyl, ~~lower~~ C_{1-7} hydroxyalkyl , ~~lower~~ C_{1-7}-alkoxy-~~lower~~ C_{1-7}-alkyl, cycloalkyl or heterocyclyl, wherein said ~~lower~~ C_{1-7} alkyl is optionally substituted by oxo, R^7 or $-N(R^8)_2$, and wherein said ~~lower~~ C_{1-7} haloalkyl is optionally substituted by hydroxyl, and wherein said cycloalkyl and said heterocyclyl are optionally substituted by 1 to 3 substituents independently selected from the group consisting of hydroxyl, halogen, ~~lower~~ C_{1-7} alkyl, ~~lower~~ C_{1-7} alkoxy, ~~lower~~ C_{1-7} hydroxyalkyl, ~~lower~~ C_{1-7} haloalkyl, ~~lower~~ C_{1-7}-alkoxy-~~lower~~ C_{1-7}-alkyl, acetyl, cyano, -C(O)-~~lower~~ C_{1-7} alkoxy and $-N(R^8)_2$, or

R^5 and R^6, together with the nitrogen atom to which they are attached, form a heterocyclyl or spiro-heterocyclyl, wherein said heterocyclyl and said spiro-heterocyclyl are optionally substituted by 1 to 3 substituents independently selected from the group consisting of hydroxyl, halogen, ~~lower~~ C_{1-7} alkyl, ~~lower~~ C_{1-7} alkoxy, ~~lower~~ C_{1-7} hydroxyalkyl, ~~lower~~ C_{1-7} haloalkyl, ~~lower~~ C_{1-7}-alkoxy-~~lower~~ C_{1-7}-alkyl, ~~lower~~ C_{1-7} alkyl-C(O)-, cyano, oxo and amino, and wherein said amino is optionally substituted by 1 or 2 substituents independently selected from the group consisting of ~~lower~~ C_{1-7} alkyl, ~~lower~~ C_{1-7} hydroxyalkyl and ~~lower~~ C_{1-7}-alkoxy-~~lower~~ C_{1-7}- alkyl;

R^7 is cycloalkyl or heterocyclyl, wherein said cycloalkyl and said heterocyclyl are optionally substituted by 1 or 2 substituents independently selected from the group consisting of ~~lower~~ C_{1-7} alkyl, ~~lower~~ C_{1-7} hydroxyalkyl, ~~lower~~ C_{1-7}-alkoxy-~~lower~~ C_{1-7}-alkyl, halogen and ~~lower~~ C_{1-7} haloalkyl;


R^8 is independently selected from the group consisting of hydrogen, ~~lower~~ C_{1-7} alkyl, ~~lower~~ C_{1-7} hydroxyalkyl and ~~lower~~ C_{1-7}-alkoxy-~~lower~~ C_{1-7}-alkyl;

R^9 is cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein said cycloalkyl, said heterocyclyl, said aryl and said heteroaryl are optionally substituted by 1 or 2 substituents independently selected from the group consisting of ~~lower~~ C_{1-7} alkyl, ~~lower~~ C_{1-7} hydroxyalkyl, ~~lower~~ C_{1-7}-alkoxy-~~lower~~ C_{1-7}-alkyl, halogen and ~~lower~~ C_{1-7} haloalkyl;

R^{19} is hydrogen or tetrahydrofuran-2-yl;

or a pharmaceutically acceptable salt thereof.


2. A compound of formula (I) according to claim 1,



(I)

wherein

A^1 and A^2 are independently selected from the group consisting of CH and N, provided that A^1 and A^2 are not N simultaneously;



is aryl or heteroaryl, wherein said aryl and said heteroaryl are optionally substituted by 1 or 2 substituents independently selected from the group consisting of ~~lower~~ C_{1-7} alkyl optionally substituted by oxo or R^7, ~~lower~~ C_{1-7} alkoxy, ~~lower~~ C_{1-7} hydroxyalkyl, ~~lower~~ C_{1-7} haloalkyl, ~~lower~~ C_{1-7}-alkoxy-~~lower~~ C_{1-7}-alkyl, ~~lower~~ C_{1-7} alkyl-C(O)-, -C(O)-N(R^8)$_2$, -N(R^8)-C(O)-~~lower~~ C_{1-7} alkyl, cyano, halogen, R^9 and amino optionally substituted by 1 or 2 substituents

independently selected from the group consisting of ~~lower~~ C_{1-7} alkyl, ~~lower~~ C_{1-7} hydroxyalkyl and ~~lower~~ C_{1-7} -alkoxy- ~~lower~~ C_{1-7} -alkyl;

R^1 is ~~lower~~ C_{1-7} alkyl optionally substituted by R^7, ~~lower~~ C_{1-7} alkoxy, ~~lower~~ C_{1-7} hydroxyalkyl, ~~lower~~ C_{1-7} haloalkyl, ~~lower~~ C_{1-7} -alkoxy- ~~lower~~ C_{1-7} -alkyl, ~~lower~~ C_{1-7} alkyl-C(O)-, cyano, halogen, R^7 or amino optionally substituted by 1 or 2 substituents independently selected from the group consisting of ~~lower~~ C_{1-7} alkyl and ~~lower~~ C_{1-7} -alkoxy- ~~lower~~ C_{1-7} -alkyl;

R^2 and R^3 are independently hydrogen or ~~lower~~ C_{1-7} alkyl;

R^4 is heteroaryl optionally substituted by 1 to 3 substituents independently selected from the group consisting of hydroxyl, halogen, ~~lower~~ C_{1-7} alkyl, ~~lower~~ C_{1-7} alkoxy, ~~lower~~ C_{1-7} hydroxyalkyl, ~~lower~~ C_{1-7} haloalkyl, ~~lower~~ C_{1-7} -alkoxy- ~~lower~~ C_{1-7} -alkyl, ~~lower~~ C_{1-7} alkyl-C(O)-, cyano and amino optionally substituted by 1 or 2 substituents independently selected from the group consisting of ~~lower~~ C_{1-7} alkyl and ~~lower~~ C_{1-7} -alkoxy- ~~lower~~ C_{1-7} -alkyl;

R^5 and R^6 are independently hydrogen, ~~lower~~ C_{1-7} alkyl optionally substituted by oxo or R^7, ~~lower~~ C_{1-7} haloalkyl, ~~lower~~ C_{1-7} cyanoalkyl, ~~lower~~ C_{1-7} hydroxyalkyl , ~~lower~~ C_{1-7} -alkoxy- ~~lower~~ C_{1-7} -alkyl, cycloalkyl or heterocyclyl, wherein said cycloalkyl and said heterocyclyl are optionally substituted by 1 to 3 substituents independently selected from the group consisting of hydroxyl, halogen, ~~lower~~ C_{1-7} alkyl, ~~lower~~ C_{1-7} alkoxy, ~~lower~~ C_{1-7} hydroxyalkyl, ~~lower~~ C_{1-7} haloalkyl, ~~lower~~ C_{1-7} -alkoxy- ~~lower~~ C_{1-7} -alkyl, acetyl, cyano and amino optionally substituted by 1 or 2 substituents independently selected from the group consisting of ~~lower~~ C_{1-7} alkyl and ~~lower~~ C_{1-7} -alkoxy- ~~lower~~ C_{1-7} -alkyl, or

R^5 and R^6, together with the nitrogen atom to which they are attached, form a heterocyclyl or spiro-heterocyclyl, wherein said heterocyclyl and said spiro-heterocyclyl are optionally substituted by 1 to 3 substituents independently selected from the group consisting of hydroxyl, halogen, ~~lower~~ C_{1-7} alkyl, ~~lower~~ C_{1-7} alkoxy, ~~lower~~ C_{1-7} hydroxyalkyl, ~~lower~~ C_{1-7} haloalkyl, ~~lower~~ C_{1-7} -alkoxy- ~~lower~~ C_{1-7} -alkyl, ~~lower~~ C_{1-7} alkyl-C(O)-, cyano, oxo and amino optionally substituted by 1 or 2 substituents independently selected from the group consisting of ~~lower~~ C_{1-7} alkyl, ~~lower~~ C_{1-7} hydroxyalkyl and ~~lower~~ C_{1-7} -alkoxy- ~~lower~~ C_{1-7} - alkyl;

R^7 is cycloalkyl or heterocyclyl, wherein said cycloalkyl and said heterocyclyl are optionally substituted by 1 or 2 substituents independently selected from the group consisting of ~~lower~~ C_{1-7} alkyl, ~~lower~~ C_{1-7} hydroxyalkyl, ~~lower~~ C_{1-7} -alkoxy- ~~lower~~ C_{1-7} -alkyl, halogen and ~~lower~~ C_{1-7} haloalkyl;


R^8 is independently selected from the group consisting of hydrogen, ~~lower~~ C_{1-7} alkyl, ~~lower~~ C_{1-7} hydroxyalkyl and ~~lower~~ C_{1-7} -alkoxy- ~~lower~~ C_{1-7} -alkyl;

R^9 is cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein said cycloalkyl, said heterocyclyl, said aryl and said heteroaryl are optionally substituted by 1 or 2 substituents independently selected from the group consisting of ~~lower~~ C_{1-7} alkyl, ~~lower~~ C_{1-7} hydroxyalkyl, ~~lower~~ C_{1-7} -alkoxy- ~~lower~~ C_{1-7} -alkyl, halogen and ~~lower~~ C_{1-7} haloalkyl;


or a pharmaceutically acceptable salt thereof.

3. The compound or a pharmaceutically acceptable salt thereof according to claims 1 - 2, wherein R^2 and R^3 are hydrogen.

4. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 - 3, wherein R^4 is 3-fluoro-phenyl, 4-fluoro-phenyl, pyridin-3-yl, 5-fluoro-pyridin-3-yl, pyrimidin-5-yl or pyrazin-2-yl.

5. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 - 4, wherein 

is selected from the group consisting of:



wherein

R^{10} is ~~lower~~ C_{1-7} alkyl, ~~lower~~ C_{1-7} -alkoxy- ~~lower~~ C_{1-7} -alkyl, ~~lower~~ C_{1-7} haloalkyl, aryl or heteroaryl, wherein said ~~lower~~ C_{1-7} alkyl is optionally substituted by cycloalkyl;

R^{11} is ~~lower~~ C_{1-7} alkyl, ~~lower~~ C_{1-7} -alkoxy- ~~lower~~ C_{1-7} -alkyl, ~~lower~~ C_{1-7} haloalkyl, ~~lower~~ C_{1-7} hydroxyalkyl or heterocyclyl, wherein said ~~lower~~ C_{1-7} alkyl is optionally substituted by cycloalkyl or heterocyclyl.

6. The compound or a pharmaceutically acceptable salt thereof according to claim 5, wherein

R^{10} is methyl, ethyl, cyclopropylmethyl, 2-methoxy-ethyl, 2,2,2-trifluoro-ethyl, 3,3,3-trifluoro-propyl, phenyl or pyridin-2-yl;

R^{11} is methyl, ethyl, isopropyl, isobutyl, cyclopropylmethyl, oxetan-2-ylmethyl, tetrahydro-furan-2-ylmethyl, tetrahydro-furan-3-ylmethyl, 2-methoxy-ethyl, 2-hydroxy-ethyl, 2,2,2-trifluoro-ethyl, 3,3,3-trifluoro-propyl or tetrahydro-furan-3-yl.

7. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 - 6, wherein R^1 is halogen, ~~lower~~ C_{1-7} alkyl, ~~lower~~ C_{1-7} alkoxy, ~~lower~~ C_{1-7} hydroxyalkyl, ~~lower~~ C_{1-7}-

alkoxy- ~~lower~~ C_{1-7}-alkyl, -C(O)-~~lower~~ C_{1-7} alkyl, -O-~~lower~~ C_{1-7} haloalkyl, cycloalkyl, heterocyclyl or amino, and wherein said heterocyclyl is optionally substituted by ~~lower~~ C_{1-7} alkyl, and wherein said amino is substituted by 1 or 2 substituents independently selected from the group consisting of ~~lower~~ C_{1-7} alkyl and ~~lower~~ C_{1-7}-alkoxy- ~~lower~~ C_{1-7}-alkyl.

8. The compound or a pharmaceutically acceptable salt thereof according to claim 7, wherein R^1 is chloro, methyl, 1-hydroxy-ethyl, 1-hydroxy-1-methyl-ethyl, isopropyl, isobutyl, tert-butyl, methoxymethyl, methoxy, 2,2,2-trifluoro-ethoxy, acetyl, cyclopropyl, cyclobutyl, cyclohexyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, azetidin-1-yl, pyrrolidin-1-yl, morpholin-4-yl, 4-methyl-piperazin-1-yl, ethyl-methyl-amino or 2-methoxy-ethylamino.

9. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 - 8,

wherein

R^5 and R^6 are independently hydrogen, ~~lower~~ C_{1-7} alkyl, ~~lower~~ C_{1-7} hydroxyalkyl, ~~lower~~ C_{1-7} alkoxy, ~~lower~~ C_{1-7} haloalkyl, ~~lower~~ C_{1-7}-alkoxy- ~~lower~~ C_{1-7}-alkyl, cycloalkyl or heterocyclyl, wherein said ~~lower~~ C_{1-7} alkyl is optionally substituted by dimethylamino or heterocyclyl, and wherein said ~~lower~~ C_{1-7} haloalkyl is optionally substituted by hydroxyl, and wherein said cycloalkyl is optionally substituted by hydroxyl, and wherein said heterocyclyl is optionally substituted by ~~lower~~ C_{1-7} alkyl or -C(O)- C_{1-7} ~~lower~~ alkoxy, or

R^5 and R^6, together with the nitrogen atom to which they are attached, form an azetidine, pyrrolidine, piperidine, morpholine, piperazine, isoxazolidine or 2-oxa-6-aza-spiro[3.3]heptane ring, wherein each of said azetidine, pyrrolidine, piperidine, morpholine, piperazine, isoxazolidine or 2-oxa-6-aza-spiro[3.3]heptane ring is optionally substituted by 1 or 2 substituents independently selected from the group consisting of hydroxyl, halogen, ~~lower~~ C_{1-7} alkyl, ~~lower~~ C_{1-7} hydroxyalkyl, ~~lower~~ C_{1-7} alkoxy, oxo and amino, and wherein said amino is substituted by 2 ~~lower~~ C_{1-7} alkyl.

10. The compound or a pharmaceutically acceptable salt thereof according to claim 9,

wherein

R^5 and R^6 are independently hydrogen, methyl, tetrahydrofuran-2-yl-methyl, ethyl, 2-methoxy-1-methyl-ethyl, 2-hydroxy-ethyl, 2-fluoro-ethyl, 2-hydroxy-1,1-dimethyl-ethyl, 2,2-difluoro-ethyl, 2,2,2-trifluoro-ethyl, 2,2,2-trifluoro-1-methyl-ethyl, 2-dimethylamino-ethyl, propyl, isopropyl, 2,3-dihydroxy-propyl, 3-hydroxy-propyl, 2-hydroxy-2-methyl-propyl, 3-hydroxy-2-methyl-propyl, 3-hydroxy-2,2-dimethyl-propyl, 2,2-difluoro-propyl, 3,3,3-trifluoro-2-hydroxy-propyl, 2-methoxy-2-methyl-propyl, butyl, isobutyl, 3-hydroxy-3-methyl-butyl, methoxy, cyclopropyl, cyclobutyl, cyclopentyl, 2-hydroxy-cyclopentyl, cyclohexyl, oxetan-3-yl, 3-methyl-oxetan-3-yl, tetrahydro-furan-3-yl, tetrahydro-pyran-4-yl, 1-methyl-azetidin-3-yl, pyrrolidin-3-yl, 1-methyl-pyrrolidin-3-yl, 1-(tert-butoxycarbonyl)pyrrolidin-3-yl, 1-methyl-piperidin-3-yl or 1-methyl-piperidin-4-yl, or

R^5 and R^6, together with the nitrogen atom to which they are attached, form an optionally substituted heterocyclyl or spiro-heterocyclyl ring selected from the group consisting of azetidin-1-yl, 3-hydroxy-azetidin-1-yl, 3-fluoro-azetidin-1-yl, 3,3-difluoro-azetidin-1-yl, pyrrolidin-1-yl, 2-methyl-pyrrolidin-1-yl, 3-hydroxy-pyrrolidin-1-yl, 3-methoxy-pyrrolidin-1-yl, 2-hydroxymethyl-pyrrolidin-1-yl, 3-dimethylamino-pyrrolidin-1-yl, 2,5-dimethyl-pyrrolidin-1-yl, 2,2-dimethyl-pyrrolidin-1-yl, 3,3-dimethyl-pyrrolidin-1-yl, 3,3-difluoro-pyrrolidin-1-yl, piperidin-1-yl, 2-methyl-piperidin-1-yl, isoxazolidin-2-yl, morpholin-4-yl, 3-oxo-piperazin-1-yl and 2-oxa-6-aza-spiro[3.3]heptan-6-yl.


11. The compound according to any one of claims 1 and 3 - 10, selected from the group consisting of:


6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyridine-2-carboxylic acid (3-dimethylcarbamoyl-1-methyl-1H-pyrazol-4-yl)-amide,

6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyridine-2-carboxylic acid (1-methyl-3-methylcarbamoyl-1H-pyrazol-4-yl)-amide,

6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyridine-2-carboxylic acid (3-carbamoyl-1-methyl-1H-pyrazol-4-yl)-amide,

6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyridine-2-carboxylic acid [3-dimethylcarbamoyl-1-(2-methoxy-ethyl)-1H-pyrazol-4-yl]-amide,



, and 

,

wherein

R^{12} is hydrogen or halogen;

R^{13} is hydrogen, ~~lower~~ C_{1-7} alkyl, ~~lower~~ C_{1-7} -alkoxy- ~~lower~~ C_{1-7} -alkyl, cycloalkyl or tetrahydrofuranyl;

R^{14} is hydrogen or ~~lower~~ C_{1-7} alkyl;

R^{15} is hydrogen or halogen;

R^{16} is hydrogen, halogen or diethylaminocarbonyl;

R^{17} is hydrogen, halogen, ~~lower~~ C_{1-7} alkyl, ~~lower~~ C_{1-7} alkoxy, ~~lower~~ C_{1-7} haloalkyl, cyano, 2-hydroxy-ethoxy, 2-methoxy-ethoxy, 2-hydroxy-2-methyl-propoxy, 2-(hydroxycarbonyl)ethyl, 2-ethoxycarbonyl-ethyl, methylcarbamoylmethoxy or acetylamino;

R^{18} is hydrogen, halogen, ~~lower~~ C_{1-7} alkyl or ~~lower~~ C_{1-7} alkoxy.

14. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 - 4 and 13, wherein R^1 is ~~lower~~ C_{1-7} alkyl or cycloalkyl.

15. The compound or a pharmaceutically acceptable salts thereof according to claim 14, wherein R^1 is isopropyl, isobutyl, tert-butyl or cyclopropyl.

16. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 - 4 and 13 - 15,

wherein

R^5 and R^6 are independently hydrogen, ~~lower~~ C_{1-7} alkyl, ~~lower~~ C_{1-7} hydroxyalkyl, ~~lower~~ C_{1-7} haloalkyl, ~~lower~~ C_{1-7} -alkoxy- ~~lower~~ C_{1-7} -alkyl, cycloalkyl or heterocyclyl, wherein said ~~lower~~ C_{1-7} alkyl is optionally substituted by heterocyclyl, and wherein said heterocyclyl is optionally substituted by ~~lower~~ C_{1-7} alkyl or


R^5 and R^6, together with the nitrogen atom to which they are attached, form an azetidine, pyrrolidine, piperidine, piperazine or 2-oxa-6-aza-spiro[3.3]heptane ring, wherein each of said azetidine, pyrrolidine, piperazine or 2-oxa-6-aza-spiro[3.3]heptane ring is optionally substituted by 1 or 2 substituents independently selected from the group consisting of hydroxyl, halogen, ~~lower~~ C_{1-7} alkyl, ~~lower~~ C_{1-7} hydroxyalkyl, ~~lower~~ C_{1-7} alkoxy, oxo and amino, and wherein said amino is substituted by 2 ~~lower~~ C_{1-7} alkyl.

17. The compound or a pharmaceutically acceptable salt thereof according to claim 16,


wherein

R^5 and R^6 are independently hydrogen, methyl, tetrahydrofuran-2-yl-methyl, ethyl, 2-hydroxy-1-methyl-ethyl, 2-hydroxy-1,1-dimethyl-ethyl, 2-methoxyethyl, 2-methoxy-1-methyl-ethyl, 2-hydroxy-ethyl, 2-isopropoxy-ethyl, 2,2,2,-trifluoro-ethyl, isopropyl, 2,3-dihydroxy-propyl, 3-hydroxy-propyl, 2-hydroxy-2-methyl-propyl, 2-methoxy-2-methyl-propyl, 3-methoxy-2,2-dimethyl-propyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahydrofuran-3-yl, oxetan-3-yl, 3-methyl-oxetan-3-yl or tetrahydro-pyran-4-yl, or

R^5 and R^6, together with the nitrogen atom to which they are attached, form an optionally substituted heterocyclyl or spiro-heterocyclyl ring selected from the group consisting of azetidin-1-yl, 3-hydroxy-azetidin-1-yl, 3,3-difluoro-azetidin-1-yl, pyrrolidin-1-yl, 2-methyl-pyrrolidin-1-yl, 3-hydroxy-pyrrolidin-1-yl, 3-methoxy-pyrrolidin-1-yl, 2-hydroxymethyl-pyrrolidin-1-yl, 3-dimethylamino-pyrrolidin-1-yl, 2,5-dimethyl-pyrrolidin-1-yl, 2,2-dimethyl-pyrrolidin-1-yl, 3,3-dimethyl-pyrrolidin-1-yl, 3,3-difluoro-



(2)



wherein A1, A2, , R1, R2, R3, R4, R5 and R6 are as defined in any of claims 1 - 19 and R is hydrogen or ~~lower~~ C_{1-7} alkyl, and if desired, converting the compound into a pharmaceutically acceptable salt thereof.

21. A compound according to any one of claims 1 - 19 for use as therapeutically active substance.

22. A pharmaceutical composition comprising a compound in accordance with any one of claims 1 - 19 and a therapeutically inert carrier.

23. The use of a compound according to any one of claims 1 - 19 for the preparation of a medicament for the treatment or prophylaxis of psychotic disorders, schizophrenia, positive, negative and/or cognitive symptoms associated with schizophrenia, delusional disorder, substance-induced psychotic disorder, anxiety disorders, panic disorder, obsessive/compulsive disorders, acute stress disorder, generalized anxiety disorder, drug addictions, movement disorders, Parkinson's disease, restless leg syndrome, cognition deficiency disorders, Alzheimer's disease, multi-infarct dementia, mood disorders, depression, bipolar disorders, neuropsychiatric conditions, psychosis, attention-deficit/hyperactivity disorder, attentional disorders, diabetes and related disorders, type 2 diabetes mellitus, neurodegenerative disorders, Huntington's disease, multiple sclerosis, stroke, spinal cord injury, solid tumors, hematological malignancies, renal cell carcinoma or breast cancer.

24. A compound according to any one of claims 1 - 19 for the treatment or prophylaxis of psychotic disorders, schizophrenia, positive, negative and/or cognitive symptoms associated with schizophrenia, delusional disorder, substance-induced psychotic disorder, anxiety disorders, panic disorder, obsessive/compulsive disorders, acute stress disorder, generalized anxiety disorder, drug addictions, movement disorders, Parkinson's disease, restless leg syndrome, cognition deficiency disorders, Alzheimer's disease, multi-infarct dementia, mood disorders, depression, bipolar disorders, neuropsychiatric conditions, psychosis, attention-deficit/hyperactivity disorder, attentional disorders, diabetes and related disorders, type 2 diabetes mellitus, neurodegenerative disorders, Huntington's disease, multiple sclerosis, stroke, spinal cord injury, solid tumors, hematological malignancies, renal cell carcinoma or breast cancer.

~~25. A compound according to any one of claims 1 - 19, when manufactured according to a process of claim 20.~~